## STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract
		Page 3
		(b) Provide in the abstract an informative and balanced summary of what was done
		and what was found
		Page 3-4
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported
		Page 5
Objectives	3	State specific objectives, including any prespecified hypotheses
		Page 6
Methods		
Study design	4	Present key elements of study design early in the paper
		Page 6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment,
		exposure, follow-up, and data collection
		Page 6-7
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of
		participants. Describe methods of follow-up
		Page 6-7
		(b) For matched studies, give matching criteria and number of exposed and
		unexposed
		N/A
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect
		modifiers. Give diagnostic criteria, if applicable
D-4/	8*	Page 7
Data sources/	8	For each variable of interest, give sources of data and details of methods of
measurement		assessment (measurement). Describe comparability of assessment methods if there is more than one group
		Page 6-7
Bias	9	Describe any efforts to address potential sources of bias
Dias	,	Page 6-7
Study size	10	Explain how the study size was arrived at
Study Size	10	Page 6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable,
		describe which groupings were chosen and why
		Page 7-8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding
		Page 8
		(b) Describe any methods used to examine subgroups and interactions
		Page 8
		(c) Explain how missing data were addressed
		N/A
		(d) If applicable, explain how loss to follow-up was addressed
		N/A
		(e) Describe any sensitivity analyses
		Page 7

Results		
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially
		eligible, examined for eligibility, confirmed eligible, included in the study,
		completing follow-up, and analysed
		Page 9-10
		(b) Give reasons for non-participation at each stage
		N/A
		(c) Consider use of a flow diagram
		Figure 1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and
		information on exposures and potential confounders
		N/A
		(b) Indicate number of participants with missing data for each variable of interest
		N/A
		(c) Summarise follow-up time (eg, average and total amount)
		Figure 1
Outcome data  Main results	15*	Report numbers of outcome events or summary measures over time
	10	Table 1
	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and
Walli results	10	their precision (eg, 95% confidence interval). Make clear which confounders were
		adjusted for and why they were included
		N/A
		(b) Report category boundaries when continuous variables were categorized
		N/A
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a
		meaningful time period
		N/A
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and
		sensitivity analyses
		Page 8-9
Discussion		
Key results	18	Summarise key results with reference to study objectives
		Page 12
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or
		imprecision. Discuss both direction and magnitude of any potential bias
		Page 15
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations,
		multiplicity of analyses, results from similar studies, and other relevant evidence
		Page 12-16
Generalisability	21	Discuss the generalisability (external validity) of the study results
		N/A
Othon information		
Other information Funding	22	Give the source of funding and the role of the funders for the present study and, if
	22	applicable, for the original study on which the present article is based
		N/A
		IV/A

<sup>\*</sup>Give information separately for exposed and unexposed groups.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at http://www.strobe-statement.org.